Neuropsychiatric Symptoms of Moyamoya Disease: Considerations for the Clinician
Carlee Oakley,Giuseppe Lanzino,James Klaas
DOI: https://doi.org/10.2147/ndt.s440975
IF: 2.989
2024-03-23
Neuropsychiatric Disease and Treatment
Abstract:Carlee I Oakley, 1 Giuseppe Lanzino, 2 James P Klaas 1 1 Department of Neurology, Mayo Clinic, Rochester, MN, USA; 2 Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA Correspondence: Carlee I Oakley, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA, Tel +1 507 284 2120, Fax +1 507 538 6012, Email Neurocognitive impairment in moyamoya disease is common, under recognized, and potentially devastating. The purpose of this paper is to provide an updated overview on this topic for the practicing clinician. We searched PubMed for keywords including cognitive impairment, neurocognitive dysfunction, and neuropsychological recovery in moyamoya disease. We summarized the literature to provide a concise review of the treatment and management of neuropsychiatric symptoms associated with moyamoya disease. Neuropsychiatric sequelae have conventionally been attributed to chronic cerebral hypoperfusion and/or stroke. Cognitive dysfunction in adults with moyamoya disease is most commonly in the form of impaired executive function, whereas intelligence is the predominant impairment in children with moyamoya disease. Pharmacotherapy for treatment of the neuropsychiatric symptoms associated with moyamoya disease is appropriate and can improve quality of life; however, careful consideration is needed to avoid adverse cerebrovascular events. It remains unclear as to whether surgical revascularization improves or stabilizes cognitive performance and outcomes. Additional prospective studies are warranted to better understand the long-term impact of revascularization on cognitive functioning in moyamoya disease. Keywords: moyamoya disease, moyamoya angiopathy-associated cognitive dysfunction, neuropsychological outcomes, neuropsychiatric comorbidity, revascularization, neurocognitive recovery Moyamoya disease (MMD) is characterized by progressive narrowing of the intracranial terminal portions of the internal carotid arteries and their proximal branches within the circle of Willis, which, in turn, leads to the formation of abnormal networks of collateral vessels near the stenotic lesions. 1 "Moyamoya" is Japanese for "puff of smoke", which is how these collateral vessels appeared on early conventional angiography. 1 The incidence of MMD in the United States is 0.086 per 100,00 person-years. 2 It is more prevalent in women than men. 3 MMD has a bimodal age of onset, with a peak in the first decade of life and a second peak at 30–40 years. 4 While the pathophysiology of MMD is not fully understood, MMD is distinct from cerebrovascular steno-occlusive disease due to atherosclerosis. 5 When the characteristic vascular changes of MMD occur in the setting of autoimmune disease, meningitis, brain tumor, Down syndrome, neurofibromatosis type 1, prior radiation, or another identifiable etiology the vasculopathy is termed moyamoya syndrome. Pediatric patients receiving radiation therapy, including proton beam therapy, for brain tumors are at increased risk of developing radiation-induced moyamoya syndrome. 6,7 MMD predisposes to not only cerebral ischemia (ie, transient ischemic attacks and ischemic strokes) due to compromised cerebral perfusion through the stenotic arteries but also intracerebral hemorrhage as the compensatory collateral vessels are fragile and prone to rupture. 8 Therefore, MMD most often presents with focal neurologic deficits including lateralizing weakness, hemisensory loss, aphasia, dysarthria, visual disturbance, and decreased consciousness. 9,10 Other common symptoms include headache, seizures, and movement disorders. 11,12 MMD can also cause neuropsychiatric sequelae, which are not only common but perhaps some of the most disabling and difficult symptoms to treat in MMD. 13–15 While rare, MMD has been reported to present with psychosis resembling schizophrenia in both children and adults. 16–18 MMD has been implicated to cause progressive cognitive decline, with cognitive dysfunction reported in 30% to 73% of patients with MMD. 19,20 The most commonly reported neurocognitive impairments in MMD differ by age group, as summarized in Table 1. Early age at onset and longer duration of disease have been associated with worse cognitive outcomes. 21,22 In pediatric patients with MMD, irreversible ischemic brain damage can have a profound impact on intellectual and functional outcomes. 23,24 Intelligence is the domain most often affected in children with MMD. 25,26 However, impairments in memory, processing speed, and visuospatial functioning have also been observed and reported. 19,20 Table 1 The Most Commonly Reported Neurocognitive Impairments in MMD by Age Gr -Abstract Truncated-
psychiatry,clinical neurology